IP Library Granted Patent US 8,658,663
Granted Patent B2
US 8,658,663 · App. 12/292,960 · Granted Feb 25, 2014

Method of treating thermoregulatory disfunction with paroxetine

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,658,663
App. No.
12/292,960
Granted
Feb 25, 2014
Kind
B2
Abstract

The present invention relates to a method for treating a patient suffering from a thermoregulatory dysfunction, especially hot flashes and flushes associated with hormonal changes due to naturally occurring menopause (whether male or female) or due to chemically or surgically induced menopause. The method is also applicable to treating the hot flashes, hot flushes, or night sweats associated with disease states that disrupt normal hormonal regulation of body temperature.

Claims (5)

1. A method for treating a patient suffering from a thermoregulatory dysfunction associated with menopause comprising administering paroxetine mesylate to said patient in an amount, based on the paroxetine moiety, of 7.5 mg/day.

2. The method of claim 1 , wherein said thermoregulatory dysfunction is a condition selected from the group consisting of hot flashes, hot flushes, night sweats and combinations thereof.

3. The method of claim 1 , wherein the paroxetine mesylate is in a crystalline form.

4. The method of claim 1 , wherein the paroxetine mesylate is in an amorphous form.

5. A method for treating a patient suffering from a thermoregulatory dysfunction associated with menopause comprising administering paroxetine to said patient, wherein said paroxetine is in the form of a pharmaceutically acceptable mesylate salt, in amorphous or crystalline form, and mixtures thereof, wherein said paroxetine mesylate is administered in an amount, based on the paroxetine moiety, of 7.5 mg/day.

Assignments (7)
SECURITY INTEREST Recorded Mar 23, 2026
From: LEGACY PHARMA INC. SEZC
To: ROOSTER LP
Reel/Frame 074151/0761 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 28, 2025
From: SEBELA IRELAND LIMITED
To: LEGACY PHARMA INC.
Reel/Frame 070028/0472 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 18, 2019
From: SEBELA INTERNATIONAL BERMUDA LIMITED
To: SEBELA IRELAND LIMITED
Reel/Frame 049791/0116 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 26, 2018
From: SEBELA INTERNATIONAL LIMITED
To: SEBELA INTERNATIONAL BERMUDA LIMITED
Reel/Frame 046200/0934 →
RELEASE OF SECURITY INTEREST Recorded Jan 30, 2018
From: HEALTHCARE FINANCIAL SOLUTIONS, LLC, AS ADMINISTRATIVE AGENT
To: SEBELA INTERNATIONAL LIMITED
Reel/Frame 045190/0810 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 3, 2016
From: NOVEN PHARMACEUTICALS, INC.; NOVEN THERAPEUTICS, LLC
To: SEBELA INTERNATIONAL LIMITED
Reel/Frame 039334/0114 →
SECURITY INTEREST Recorded Jul 26, 2016
From: SEBELA INTERNATIONAL LIMITED
To: HEALTHCARE FINANCIAL SOLUTIONS, LLC, AS ADMINISTRATIVE AGENT
Reel/Frame 039260/0962 →